Superworth

Illumina ILMN

Medical - Diagnostics & Research, Healthcare
$236.60
+4.42%
Market cap
$35.7B
PE
44.0×
10y median 51.3×
Forward PE
41.5×
10y median 56.0×
Price to sales
8.0×
EV/EBIT
36.6×
Revenue, 12 months
$4.5B
+5% on a year ago
Net margin
18.4%
Free cash flow yield
2.6%

Illumina trades at 44.0× trailing earnings, cheaper than 69% of the last ten years. Revenue was $4.5B over the last twelve months, up 5% on a year earlier with a 18% net margin.

Charts

Financials

Income statement for ILMN, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$1.1B+0%$1.1B+4%$1.1B−1%$1.1B−5%$1.1B−4%$1.1B−2%$1B−3%$1.1B−5%$1.1B+0%$1.2B+5%$1.1B+5%$1.2B+9%
Cost of revenue$435M+9%$448M+9%$409M−5%$391M−12%$335M−23%$376M−16%$358M−13%$364M−7%$351M+5%$400M+6%$370M+3%$389M+7%
Gross profit$684M−5%$674M+0%$667M+2%$721M−2%$745M+9%$728M+8%$683M+2%$695M−4%$733M−2%$759M+4%$721M+6%$770M+11%
R&D$315M−3%$341M−1%$339M−1%$325M−9%$253M−20%$256M−25%$252M−26%$247M−24%$229M−10%$239M−7%$240M−5%$252M+2%
SG&A$303M+108%$485M+12%$439M+16%$147M−68%$239M−21%$279M−43%$267M−39%$234M+59%$277M+16%$309M+11%$272M+2%$273M+17%
−$754M−79%−$164M+29%−$111M+73%−$1.6B+1760%$741M$175M$164M$214M$227M−69%$201M+15%$209M+27%$245M+15%
Interest expense$19M+217%$18M+100%$18M−10%$20M+5%$36M+90%$25M+39%$25M+39%$25M+25%$25M−31%$26M+4%$24M−4%$24M−4%
Pre-tax income−$782M−79%−$167M−1%−$109M+40%−$2B+2120%$720M$187M$182M$306M$220M−69%$377M+102%$157M−14%$260M−15%
−$28M$8M$17M$12M−92%$15M$0$51M+200%$71M+492%$70M+367%$43M$23M−55%$53M−25%
Net income−$754M−80%−$175M+26%−$126M−$2B+750%$705M$187M$131M$235M$150M−79%$334M+79%$134M+2%$207M−12%
−$4.77−80%−$1.11+25%−$0.79−$12.48+743%$4.42$1.18$0.82$1.49$0.98−78%$2.18+85%$0.87+6%$1.35−9%
158M+1%158M+1%159M+1%159M+1%160M+1%159M+1%159M+0%157M−1%154M−4%153M−4%154M−3%153M−3%

EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 15 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22 and Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$1.2B$1.1B to $1.2B$1.36$1.35 to $1.3712
Q4 FY26$1.2B$1.2B to $1.2B$1.53$1.41 to $1.5612
Q1 FY27$1.2B$1.1B to $1.2B$1.35$1.16 to $1.478
Q2 FY27$1.2B$1.2B to $1.2B$1.48$1.45 to $1.503
Q3 FY27$1.2B$1.2B to $1.3B$1.59$1.55 to $1.615
Q4 FY27$1.3B$1.3B to $1.3B$1.74$1.70 to $1.773
Q1 FY28$1.2B$1.2B to $1.3B$1.66$1.62 to $1.686
Q2 FY28$1.3B$1.3B to $1.3B$1.80$1.76 to $1.834

Peers

Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ILMNIllumina$35.7B44.0×51.3×41.5×8.0×+5%18.4%
MTDMettler-Toledo International$34.2B38.4×36.6×34.6×8.3×+7%21.9%
LHLabcorp$28.9B29.4×19.5×18.8×2.0×+6%7.0%
DGXQuest Diagnostics$27.5B24.9×19.3×n/m2.3×+9%9.5%
IQVIQVIA$42.5B32.0×34.8×19.0×2.5×+8%8.1%
WATWaters$46.4B118×29.2×30.4×10.0×+52%3.6%
AAgilent Technologies$49.6B34.5×33.2×26.8×6.7×+9%19.5%
IDXXIDEXX Laboratories$52.1B46.5×54.9×42.4×11.4×+13%25.0%
MEDPMedpace$18.1B38.0×34.5×n/m6.5×+25%17.7%
RVTYRevvity$16.9B72.2×35.1×n/m5.8×+4%8.2%
BIOBio-Rad Laboratories$9.8B44.4×30.9×n/m3.8×+1%8.6%
Peer median$31.5B38.2×33.8×28.6×6.2×+8%9.1%

Investors who own it

Investors we follow who held Illumina at the end of Jun 30, 2026, from their 13F filings.

More on Illumina

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .